19:59 , Jun 15, 2018 |  BC Week In Review  |  Financial News

Immunovia issues $37.3M in new shares

Diagnostic company Immunovia AB (SSE:IMMNOV) raised SEK324.4 million ($37.3 million) on June 8 in a new share issue of 2.2 million shares at SEK150. Investors included Swedbank Robur, Handelsbanken Fonder, Alfred Berg Kapitalförvaltning, Nyenburgh Investment...
23:00 , Apr 4, 2017 |  BC Extra  |  Financial News

Isofol raises SEK430M in IPO

Isofol Medical AB (SSE:ISOFOL) lost SEK2 to SEK27 in its first day of trading Tuesday after raising SEK430 million ($48 million) through the sale of 14.8 million shares at SEK29 in an IPO underwritten by...
02:02 , Jan 28, 2006 |  BC Extra  |  Financial News

Genmab raises $119.5 million

Genmab (CSE:GEN) raised DKK735 million ($119.5 million) through a private placement of 5 million shares at DKK147, which was GEN's closing price on Thursday. Merrill Lynch; Alfred Berg; and ABN AMRO Rothschild managed the placement....
08:00 , Dec 12, 2005 |  BioCentury  |  Finance

Ebb & Flow

Even after this month's blowup at Rigel (RIGL), when Phase II data for its R112 allergic rhinitis candidate did not pan out, VCs who led the company's PIPE in April 2003 still look to have...
02:36 , Dec 6, 2005 |  BC Extra  |  Top Story

Zealand withdraws IPO

Five days after issuing its prospectus, Zealand (Glostrup, Denmark) withdrew its planned IPO because it could not obtain a satisfactory price. The company had hoped to list on the Copenhagen Stock Exchange through ABN-AMRO Rothschild/Alfred...
08:00 , Dec 5, 2005 |  BioCentury  |  Finance

Ebb & Flow

IPO activity has been percolating in France, where ExonHit (Euronext:ALEHT) recently went public on Alternext and has seen investors clamoring to get shares of the alternative splicing company. At Friday's close of E3.70, ALEHT is...
03:41 , Nov 29, 2005 |  BC Extra  |  Financial News

Zealand files for IPO

Zealand (Glostrup, Denmark) filed to sell 4 million shares in an IPO on the Copenhagen Stock Exchange through ABN-AMRO Rothschild/Alfred Berg and Carnegie. Zealand has three compounds in Phase II trials: ZP10 ( AVE0010), a...
07:00 , Jul 1, 2004 |  BC Extra  |  Financial News

GenMab raises DKK478 million

Antibody company GenMab (CSE:GEN) raised DKK478 million ($78.2 million) through the sale of 5.6 million shares at DKK85 ($13.91) in an international private placement managed by Merrill Lynch; Alfred Berg Bank; and ABN AMRO Rothschild....
07:00 , Jun 21, 2004 |  BioCentury  |  Finance

Ebb & Flow

European investors signaled last week that they will take as hard a line on European IPOs as investors have been taking in the U.S. And given its cash position, the company that tested the waters,...
07:00 , Jun 18, 2004 |  BC Extra  |  Financial News

GenMab plans private placement

Antibody company GenMab (CSE:GEN) plans to sell up to 4.9 million shares in an international private placement. If sold in full at Thursday's close of DKK101 ($16.33), GEN would raise DKK494.9 million ($80 million) prior...